# A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

> **NCT03957590** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 370 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Placebo
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03957590
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-11
- **Primary completion:** 2025-01-08
- **Final completion:** 2025-03-31
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957590, "A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03957590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*